Tags

Type your tag names separated by a space and hit enter

Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
Prev Cardiol. 2008 Fall; 11(4):215-22.PC

Abstract

As presented previously in Part 1 of this 2-part article, many long-term clinical trials provide overwhelming evidence of the benefits of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) across the cardiovascular continuum. Trials also indicate additive or synergistic effects of combination therapy in renal disease and heart failure. Part 2, which is presented here, discusses the extensive interaction of the renin-angiotensin system (RAS) with the cellular and molecular pathophysiology of cardiovascular disease and the cross-continuum effects of ARBs and ACE inhibitors, which raises the possibility that RAS inhibition can offer protection in high-risk patients who do not have symptoms. Although trial evidence supports the effectiveness of monotherapy, the benefits of combined ACE inhibitor/ARB therapy in high-risk patients await confirmation. Ongoing clinical research will provide new and important information regarding the efficacy of specific combination (ACE inhibitor/ARB) therapies.

Authors+Show Affiliations

University of California Davis Medical Center, Sacramento, 95817, USA. william.bommer@ucdmc.ucdavis.edu

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

19476574

Citation

Bommer, William J.. "Use of Angiotensin-converting Enzyme Inhibitor/angiotensin Receptor Blocker Therapy to Reduce Cardiovascular Events in High-risk Patients: Part 2." Preventive Cardiology, vol. 11, no. 4, 2008, pp. 215-22.
Bommer WJ. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2. Prev Cardiol. 2008;11(4):215-22.
Bommer, W. J. (2008). Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2. Preventive Cardiology, 11(4), 215-22. https://doi.org/10.1111/j.1751-7141.2008.00004.x
Bommer WJ. Use of Angiotensin-converting Enzyme Inhibitor/angiotensin Receptor Blocker Therapy to Reduce Cardiovascular Events in High-risk Patients: Part 2. Prev Cardiol. 2008;11(4):215-22. PubMed PMID: 19476574.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2. A1 - Bommer,William J, PY - 2009/5/30/entrez PY - 2009/5/30/pubmed PY - 2009/6/16/medline SP - 215 EP - 22 JF - Preventive cardiology JO - Prev Cardiol VL - 11 IS - 4 N2 - As presented previously in Part 1 of this 2-part article, many long-term clinical trials provide overwhelming evidence of the benefits of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) across the cardiovascular continuum. Trials also indicate additive or synergistic effects of combination therapy in renal disease and heart failure. Part 2, which is presented here, discusses the extensive interaction of the renin-angiotensin system (RAS) with the cellular and molecular pathophysiology of cardiovascular disease and the cross-continuum effects of ARBs and ACE inhibitors, which raises the possibility that RAS inhibition can offer protection in high-risk patients who do not have symptoms. Although trial evidence supports the effectiveness of monotherapy, the benefits of combined ACE inhibitor/ARB therapy in high-risk patients await confirmation. Ongoing clinical research will provide new and important information regarding the efficacy of specific combination (ACE inhibitor/ARB) therapies. SN - 1751-7141 UR - https://www.unboundmedicine.com/medline/citation/19476574/Use_of_angiotensin_converting_enzyme_inhibitor/angiotensin_receptor_blocker_therapy_to_reduce_cardiovascular_events_in_high_risk_patients:_part_2_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1520-037X&date=2008&volume=11&issue=4&spage=215 DB - PRIME DP - Unbound Medicine ER -